Medical Device Definition and Product Owner under Thai Law

1. Key takeaways

The Thai definition of a medical device is set out in Article 4 of the Medical Device Act B.E. 2551 (2008) together with its subsequent amendments. The working test is whether the intended purpose of the product, as claimed by the manufacturer, matches the statutory device definition. The Thai FDA officially advises that when judging whether a product is a device, clear and detailed information must be obtained from the manufacturer or the product owner, including labels, instructions for use and accompanying documents, and the intended purpose must then be assessed against the Article 4 definition. Around this definition sit several concepts that foreign teams routinely get wrong: the product owner, the treatment of software, and the boundary against cosmetics and ordinary IT products. Getting each of them right at the start determines the submission pathway, the dossier depth, the fees and the timeline for everything that follows.

• The definition anchor is Article 4 of the Medical Device Act B.E. 2551 (2008) and its later amendments; the decisive input is the intended purpose and the manufacturer claims.
• The product owner is the party holding the brand or trade name and deciding the intended purpose; it is the core anchor of the Thai grouping rules and the issuer of the Letter of Authorisation (LoA).
• Product owner and licence holder are not the same thing: the foreign manufacturer acts as product owner and authorises the Thai licence holder through the LoA.
• Software with a medical intended purpose (SaMD) is regulated as a device and classified by intended use; the B.E. 2568 (2025) labelling rules add software-specific requirements including electronic presentation, version number and UDI where applicable.
• Typical misjudgments include drug-containing dressings treated as ordinary dressings, diagnostic AI software treated as ordinary IT, and aesthetic devices treated as cosmetics.
• Where classification is uncertain, the Thai FDA product identification channel provides an official determination at a cost far below the cost of getting it wrong.

2. Legal basis

The product owner concept deserves a precise statement because it drives several downstream mechanisms. A product owner is the party that owns the brand or trade name of the device and decides its intended purpose. In the Thai system it is the core anchor of the grouping rules: one of the preconditions for combining multiple devices into a single grouped submission is that they share the same product owner. The product owner is also the party that issues the Letter of Authorisation. The critical distinction is that the product owner is not the licence holder. The foreign manufacturer, acting as product owner, uses the LoA to authorise the Thai local licence-holding entity to file and hold the registration. This separation resembles the logic seen in Vietnam under Article 2.5 of Decree 98 and in Malaysia under the authorised representative model, but Thailand goes one step further: the licence-holding entity must also be the importer.

On software, the position is clear: software with a medical intended purpose is a device, managed as such and classified according to its intended use. In addition, the B.E. 2568 (2025) labelling notification singles out software and applications: labels and instructions for use may be presented in electronic form and must carry the version number and, where applicable, the UDI. On boundaries, Thailand applies specific sales licence requirements to teeth whitening devices, silicone breast implants and injectable hyaluronic acid fillers, which confirms that these items are devices rather than cosmetics, and that cosmetic rules can never be relied on for them.

3. Expert insights

The most expensive classification mistakes in Thailand come from three recurring patterns. First, a dressing that contains a drug is treated as an ordinary dressing, which understates both the class and the dossier. Second, AI software that produces diagnostic output is treated as an ordinary IT system, which removes it from device control entirely. Third, aesthetic devices are treated as cosmetics, which is directly contradicted by the Thai sales licence requirements for teeth whitening devices, silicone breast implants and injectable hyaluronic acid fillers. Each of these errors sends the product down the wrong submission pathway, leading to rejection at review or, worse, to a finding of unlicensed circulation after market entry. The practical estimate is simple: a product identification application costs a fraction of the rework caused by a wrong classification discovered mid-programme, so the economic choice is never in doubt. This is also why classification disputes should be resolved before dossier work begins, not after.

4. Practical recommendations

• Never settle a borderline classification by internal discussion alone; either use the Thai FDA product identification and classification confirmation channel, or ask the Thai licence holder for precedent based on comparable submissions it has filed.
• Collect the definition inputs before anything else: labels, instructions for use and accompanying documents from the manufacturer or product owner, since the Thai FDA assessment of Article 4 depends on them.
• Treat the foreign manufacturer as product owner and the Thai entity as licence holder from day one, and put the LoA chain in place before dossier preparation starts.
• For SaMD, plan for the B.E. 2568 software labelling requirements early, including electronic presentation, version numbering and UDI where applicable.
• Screen every product line for the three classic misjudgment patterns, drug-containing dressings, diagnostic AI and aesthetic devices, before selecting a submission pathway.

5. Verification checklist

• □ Medical Device Act B.E. 2551 (2008) Article 4 definition and subsequent amendments confirmed (pending verification).
• □ Thai FDA website What is medical devices definition page confirmed (pending verification).
• □ Thai FDA product identification application channel at medical.fda.moph.go.th confirmed (pending verification).
• □ Thai FDA list of products subject to sales licence, covering teeth whitening devices, silicone breast implants and hyaluronic acid fillers (pending verification).
• □ MoPH labelling notification B.E. 2568 (2025), software and application provisions confirmed (pending verification).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Thailand. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the Thai FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com